Actively Recruiting
Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-07-11
72
Participants Needed
1
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the MAPEG 2 study is to explore gustatory function and to follow its evolution in the 4 following groups of participants: * Healthy subjects * Participants with isolated cognitive complaint * Participants with minor neurocognitive disorder * Participants with mild and moderate Alzheimer-type major neurocognitive disorders For this purpose, we want to compare the results of the following tests: * Subjective taste tests (tasting solutions, answering food preference questionnaires), * Gustatory evoked potential (GEP) parameters, recorded by electrodes placed on the scalp, * And nutritional parameters (hormones of food intake by blood test, measurement of the global body composition). Identifying and following the evolution of early taste disorders in case of cognitive disorders could improve the diagnosis of Alzheimer\'s disease in two ways: * To allow an early diagnosis of Alzheimer\'s disease, and thus improve its management, * To define groups of subjects at risk of developing Alzheimer\'s disease in later years.
CONDITIONS
Official Title
Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Person who has given oral consent.
- For patients with mild to moderate Alzheimer's disease, the primary caregiver and the patient will be asked to provide oral consent.
- Person of legal age.
- Body Mass Index (BMI) < 30 kg/m².
- For the healthy group: absence of cognitive complaints and normal neurological assessment.
- Patients with isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation.
- Patients with minor cognitive impairment: brain MRI and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5.
- Patients with mild to moderate Alzheimer's disease: brain MRI, neuropsychobiological criteria (neuropsychological assessment, CSF biomarkers), Mini-Mental State Examination (MMSE) score ≥ 20, and CDR score of 1 or 1.5.
- Fasting for at least 2 hours before gustatory evoked potential measurement.
You will not qualify if you...
- MMSE score < 15.
- Known COVID-19 infection within 6 months prior to inclusion.
- Person not affiliated to national health insurance system.
- Person under legal protection measures (curatorship, guardianship).
- Pregnant, parturient, or breastfeeding women.
- Subjects with a pacemaker (contraindicated for bioelectrical impedance measurement).
- Adult unable to express consent or perform cognitive tests.
- Active smoker (> 4 cigarettes per day regularly).
- Diabetic subject (type 1 or type 2).
- Subject with acute or chronic ENT disease.
- Treatment interfering with taste.
- Brain MRI showing another cause of neurocognitive disorder (except vascular lesions Fazekas 1 accepted).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Dijon Bourgogne
Dijon, France
Actively Recruiting
Research Team
A
Agnès JACQUIN-PIQUES
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here